Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin

Abstract

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

1 . A method for improving glycemic control compared with placebo in a type 2 diabetes patient, said method comprising administering linagliptin 5 mg qd for at least 24 weeks,
 as monotherapy wherein the patient is a drug naïve type 2 diabetes patient, or   as add-on combination therapy with metformin wherein the patient is a type 2 diabetes patient with insufficient glycemic control on metformin, or   as add-on combination therapy with metformin and a sulfonylurea wherein the patient is a type 2 diabetes patient with insufficient glycemic control on the combination of metformin and a sulfonylurea.   
     
     
         2 . The method according to  claim 1 , wherein improving glycemic control is reducing HbA1c, FPG and/or PPG. 
     
     
         3 . The method according to  claim 1 , wherein linagliptin 5 mg qd is administered for at least 24 weeks as monotherapy wherein the patient is a drug naïve type 2 diabetes patient. 
     
     
         4 . The method according to  claim 1 , wherein linagliptin 5 mg qd is administered for at least 24 weeks as add-on combination therapy with metformin wherein the patient is a type 2 diabetes patient with insufficient glycemic control on metformin. 
     
     
         5 . The method according to  claim 1 , wherein linagliptin 5 mg qd is administered for at least 24 weeks as add-on combination therapy with metformin and a sulfonylurea wherein the patient is a type 2 diabetes patient with insufficient glycemic control on the combination of metformin and a sulfonylurea. 
     
     
         6 . The method according to  claim 1 , wherein the patient is of TCF7L2 rs7903146 CC, CT or TT genotype.